SA
IONS icon

Sovran Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Sovran Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.7M Buy
+84,984
New +$6.4M 0.35% 73
2025
Q4 		– Sell
-150,856
Closed -$11.2M – 569
2025
Q3 		$11.2M Sell
150,856
-171,057
-53% -$8.35M 0.99% 18
2025
Q2 		$13.3M Sell
321,913
-6,991
-2% -$229K 1.39% 10
2025
Q1 		$9.34M Buy
328,904
+157,092
+91% +$5.14M 1.21% 15
2024
Q4 		$5.62M Buy
+171,812
New +$6.42M 0.8% 28

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Sovran Advisors's IONS Position: Q2 2026 in Review

Sovran Advisors opened a new position in Ionis Pharmaceuticals (IONS) in Q2 2026: 84,984 shares worth $4.7M. The stake represents 0.35% of the portfolio and ranks #73 among its holdings. This is a return to the name: Sovran Advisors previously reported a position in IONS as recently as Q3 2025.

Sovran Advisors first reported a position in IONS in Q4 2024 and has held it in 5 quarters since. The position peaked at $13.3M in Q2 2025. 511 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Sovran Advisors held 84,984 shares of Ionis Pharmaceuticals worth $4.7M as of Q2 2026.
  • Ionis Pharmaceuticals was a new Sovran Advisors position in Q2 2026.
  • Ionis Pharmaceuticals made up 0.35% of Sovran Advisors's portfolio in Q2 2026, its #73 holding.
  • Sovran Advisors first reported a position in Ionis Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Sovran Advisors's Ionis Pharmaceuticals position peaked at $13.3M in Q2 2025.
  • 511 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Sovran Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.